Parkinson’s disease as a somato-cognitive action network disorder
Summary
This large multimodal study repositions Parkinson’s disease (PD) from a purely effector-specific motor disorder to one centred on a somato-cognitive action network (SCAN). Using resting-state fMRI, electrophysiology and multiple intervention cohorts (DBS, adaptive DBS, TMS, MRgFUS and levodopa challenge; total n ≈ 863 after QC), the authors show that key subcortical PD nodes (substantia nigra, STN, VIM/CM thalamus, GPi, GPe and putamen) preferentially connect to the SCAN rather than classical hand/foot/mouth motor regions. In PD, cortico–subcortical SCAN connectivity is elevated (hyperconnected) compared with controls and other movement disorders. Effective treatments — levodopa, DBS and SCAN-targeted rTMS — reduce this hyperconnectivity, and stimulation sites that work clinically tend to be those that engage the SCAN. Targeting cortical SCAN nodes with personalised rTMS produced faster and larger motor improvements than effector-based stimulation in a randomised small trial. The authors propose conceptualising PD as a SCAN disorder and suggest SCAN-guided targeting as a way to refine neuromodulation and non-invasive therapies.
Key Points
- SCAN is a distinct cortical motif that alternates with effector-specific motor regions along the central sulcus.
- Six canonical PD subcortical nodes (SN, STN, VIM/CM, GPi, GPe, putamen) show stronger functional connectivity to the SCAN than to effector motor regions.
- Patients with PD exhibit SCAN cortico–subcortical hyperconnectivity versus healthy controls; this pattern is absent in ET, dystonia and ALS cohorts used as controls.
- Clinically effective DBS sweet spots (STN, GPi, VIM) and DBS-evoked cortical responses preferentially engage the SCAN, not effector-only motor cortex.
- Levodopa and STN-DBS reduce SCAN hyperconnectivity; changes in STN–SCAN connectivity correlate with motor improvement.
- Personalised rTMS targeting SCAN nodes produced larger and faster motor gains than effector-targeted rTMS and reduced SCAN hyperconnectivity.
- MRgFUS lesion outcomes correlated with proximity to thalamic SCAN hotspots, suggesting SCAN-guided lesion/stimulation targeting could optimise results.
- SCAN hyperconnectivity may be a non-invasive fMRI biomarker for PD and a guide for personalised circuit therapies (invasive and non-invasive).
Content summary
The authors collected and analysed a large, multimodal dataset (11 cohorts, total n ≈ 863). They first mapped the SCAN motif and confirmed that six subcortical nodes central to PD pathophysiology are more strongly connected to SCAN than to effector motor areas. In matched-case analyses, SCAN–subcortical connectivity was significantly elevated in PD and replicated across independent cohorts. Electrophysiological recordings during STN stimulation showed stronger evoked cortical responses in SCAN regions than in effector motor zones. Longitudinal DBS-fMRI and levodopa challenge data demonstrated that effective treatments attenuate SCAN hyperconnectivity, and rTMS targeted to personalised SCAN sites outperformed effector-based stimulation in a randomised, blinded trial of 36 patients. A focused ultrasound cohort further suggested that clinical benefit correlates with lesion proximity to thalamic SCAN nodes. The paper integrates imaging, stimulation, electrophysiology and clinical outcomes to argue that SCAN dysfunction sits at the core of PD manifestations.
Context and relevance
This work reframes PD as a network disorder implicating a somato‑cognitive action network that integrates motor planning/execution with autonomic, arousal and bodily states. It explains why many PD signs are non-effector-specific (axial symptoms, gait, bradykinesia, apathy, autonomic dysfunction) and why cognitive/attentional state modulates motor signs. The findings connect established therapeutic nodes (STN, GPi, VIM) to a common cortical network and show that both pharmacological and neuromodulatory treatments converge on normalising SCAN hyperconnectivity. For clinicians and researchers, SCAN mapping offers a path to personalise and expand neuromodulation options (cortical TMS or implanted cortical strips, DBS or focused ultrasound) and to develop imaging biomarkers for diagnosis, monitoring and treatment selection.
Why should I read this
Quick and honest: if you care about how PD symptoms hang together — and especially if you’re interested in neuromodulation or personalised targets — this paper is a goldmine. It pulls together big imaging samples, stimulation data and a small randomised TMS trial to say: stop only thinking about limb motor maps — PD really lights up a broader body–mind action network that we can measure and modulate. Short version: it changes how we might choose targets for DBS, TMS or focused ultrasound, and gives a candidate biomarker to track treatment effect.
Author style
Punchy. The authors make a strong, evidence-backed argument for reclassifying PD as a SCAN disorder and emphasise translational implications — from optimising DBS placement to using personalised cortical stimulation in patients unsuited to deep surgery. If you work in movement disorders, neuromodulation, or functional neuroimaging, the details and methods here are highly relevant.